September 2, 2017

Natural product-derived therapy for Chronic Myeloid leukaemia (CML): A pharmacological mixture encompassing β-Cryptoxanthin and Nimbolide (CN) decreases the expression of Musashi2, inhibits cytosolic aminotransferase BCAT1 expression, decreases the intracellular production of BCAAs (Branched-chain amino acids), increases the expression of tumor suppressor genes, promotes differentiation of CML cells, and inhibits cancer progression in Myeloid leukemia via up-regulation of its target gene, 3/September/2017, 1.30 am

Introduction: What they say: A study from the Department of Biochemistry-Molecular Biology, Franklin College of Arts and Sciences, The University of Georgia, Athens, Georgia 30602, USA; […]
September 1, 2017

 Natural product-based PD-1 pathway blockade for Human cancer therapy: Lovastatin, a cholesterol lowering drug, decreases the expression of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 1/September, 2017, 10.54 pm

Introduction:What they say:  A recent study from Cell Signalling Section, Division of Immunology, Department of Pathology, Tennis Court Road, University of Cambridge, Cambridge CB2 1QP, UK shows that “Glycogen Synthase […]
August 30, 2017

Natural product-derived CDK4/6 pathway blockade enhances the efficacy of Cancer immunotherapy: A pharmacological mixture encompassing natural products Berberine, Nimbolide, N-Acetyl-cysteine (BNN) and the anticancer drug Doxorubicin(D) inhibits the expression of cell cycle protein CDK4/CDK6, increases levels of T-III IFNs, inhibits the proliferation of Treg cells, decreases DNMT1 expression, inhibits the expression of a number of immune evasion molecules, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target genes, 31/August/2017, 1.33 am

Introduction:What they say: A recent study from Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands has identified […]
August 29, 2017

Natural product-derived  therapy for enhancing anti-cancer immunity: Dihydroartemisinin (DHA), a derivative of Artemisinin isolated from Artemesia anuua L, decreases the level of LATS1/2 (large tumor suppressor 1 and 2), increases immunogenicity of tumors, enhances anti-tumor immune responses, and inhibits tumor growth via down regulation of its target gene, 30/August/2017, 1.26 am

Introduction: What they say:  A study from the Department of Pharmacology and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA shows that […]